Old Lyme, CT, United States of America

Eileen Elliott Mueller


 

Average Co-Inventor Count = 6.2

ph-index = 9

Forward Citations = 460(Granted Patents)


Company Filing History:


Years Active: 2004-2018

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Eileen Elliott Mueller: Innovator in Monoclonal Antibody Development

Introduction

Eileen Elliott Mueller, based in Old Lyme, CT, is a distinguished inventor with a remarkable portfolio of 11 patents. Her contributions to the field of biomedical science, particularly in the development of monoclonal antibodies, have significantly advanced therapeutic approaches in immunology.

Latest Patents

One of her most notable patents involves the creation of human monoclonal antibodies targeting the cytotoxic T-lymphocyte antigen 4 (CTLA-4). This invention details fully human monoclonal antibodies and encompasses nucleotide sequences that encode heavy and light chain immunoglobulin molecules. The focus is on contiguous heavy and light chain sequences that span the complementarity determining regions (CDRs). The patent further provides information on antibodies with similar binding properties and functionalities, which are essential for effective cancer immunotherapy.

Career Highlights

Throughout her career, Eileen has made significant contributions while working with leading organizations in the biotechnology field. Notably, she has held positions at the Pfizer Corporation and Amgen Fremont Inc., where her expertise has driven innovation in drug development and therapeutic solutions.

Collaborations

Eileen has collaborated with esteemed colleagues, including Douglas Charles Hanson and Mark Joseph Neveu. These collaborations have fostered an environment of innovation, allowing them to work together on groundbreaking projects that have propelled advancements in monoclonal antibody research.

Conclusion

Eileen Elliott Mueller's extensive work in the area of monoclonal antibodies has made her a pivotal figure in the biomedical field. Her patents not only highlight her ingenuity but also demonstrate her commitment to improving healthcare outcomes. As the landscape of medical science evolves, innovators like Eileen will continue to play an essential role in developing therapies that transform patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…